What are the best treatments for Hyper-IgD Syndrome / Hyperimmunoglobulinemia D With Recurrent Fever (HIDS)?

Hyper-IgD Syndrome (HIDS), also known as Mevalonate Kinase Deficiency (MKD), is managed primarily through interleukin-1 (IL-1) inhibitors that target the underlying inflammatory pathway. While there is no definitive cure, current treatments focus on reducing the frequency and severity of recurrent fever episodes and systemic inflammation.

What are the current first-line treatments for HIDS?

Treatment for Hyper-IgD Syndrome is highly personalized based on disease severity. Historically, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids were used to manage acute flares, but they are often insufficient for long-term control. Today, the standard of care involves biological therapies that block IL-1, a key cytokine in Hyper-IgD Syndrome inflammation. Commonly prescribed medications include:

• Anakinra (Kineret): A daily injectable IL-1 receptor antagonist often used to prevent or shorten fever attacks.


• Canakinumab (Ilaris): A long-acting monoclonal antibody targeting IL-1β, typically administered as a subcutaneous injection every 4 to 8 weeks.


• Rilonacept (Arcalyst): Another IL-1 inhibitor sometimes utilized in the management of autoinflammatory conditions like Hyper-IgD Syndrome.

Which specialists should be on the care team?

Managing Hyper-IgD Syndrome requires a multidisciplinary approach to address systemic symptoms. Your care team should ideally include:

• Pediatric or Adult Rheumatologist: The primary lead for managing inflammatory flares and biological therapies.


• Clinical Geneticist: Essential for confirming the MVK gene mutation and providing family counseling.


• Immunologist: To monitor immune function and the efficacy of cytokine-targeted treatments.


• Gastroenterologist: Often needed, as many patients with Hyper-IgD Syndrome experience significant abdominal pain and diarrhea during flares.

How does treatment effectiveness vary between patients?

Response to therapy in Hyper-IgD Syndrome is highly variable. While some patients achieve near-complete remission with IL-1 inhibitors, others may experience breakthrough symptoms or variable responses. Disease severity ranges from mild, intermittent fevers to more severe phenotypes involving systemic organ involvement. Currently, researchers are exploring targeted therapies and gene-based interventions in clinical trials to improve outcomes for those with refractory Hyper-IgD Syndrome.

Next steps

• Consult with a rheumatologist specializing in autoinflammatory diseases to discuss personalized biological therapy options.


• Connect with the 6 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Maintain a detailed fever diary to track trigger factors, duration, and medication response for your clinical team.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your specialized healthcare team for diagnosis and treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Mevalonate Kinase Deficiency.


• Orphanet: Hyperimmunoglobulinemia D with periodic fever syndrome.


• OMIM (Online Mendelian Inheritance in Man): Mevalonate Kinase Deficiency (Entry #251170).


• Autoinflammatory Alliance: Patient resources for HIDS/MKD.